Nature Communications (May 2021)
Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice
- Eva Conde,
- Romain Bertrand,
- Bianca Balbino,
- Jonathan Bonnefoy,
- Julien Stackowicz,
- Noémie Caillot,
- Fabien Colaone,
- Samir Hamdi,
- Raïssa Houmadi,
- Alexia Loste,
- Jasper B. J. Kamphuis,
- François Huetz,
- Laurent Guilleminault,
- Nicolas Gaudenzio,
- Aurélie Mougel,
- David Hardy,
- John N. Snouwaert,
- Beverly H. Koller,
- Vincent Serra,
- Pierre Bruhns,
- Géraldine Grouard-Vogel,
- Laurent L. Reber
Affiliations
- Eva Conde
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
- Romain Bertrand
- Neovacs SA
- Bianca Balbino
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
- Jonathan Bonnefoy
- Neovacs SA
- Julien Stackowicz
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
- Noémie Caillot
- Neovacs SA
- Fabien Colaone
- Neovacs SA
- Samir Hamdi
- Neovacs SA
- Raïssa Houmadi
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III
- Alexia Loste
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III
- Jasper B. J. Kamphuis
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III
- François Huetz
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
- Laurent Guilleminault
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III
- Nicolas Gaudenzio
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III
- Aurélie Mougel
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III
- David Hardy
- Institut Pasteur, Experimental Neuropathology Unit
- John N. Snouwaert
- Department of Genetics, University of North Carolina at Chapel Hill
- Beverly H. Koller
- Department of Genetics, University of North Carolina at Chapel Hill
- Vincent Serra
- Neovacs SA
- Pierre Bruhns
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
- Géraldine Grouard-Vogel
- Neovacs SA
- Laurent L. Reber
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
- DOI
- https://doi.org/10.1038/s41467-021-22834-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Asthma is caused by hyperreactivity to benign antigens, with humoral immunity orchestrated by interleukin-4 (IL-4) and IL-13 being the key etiological factor. Here the authors show, in humanized mouse models, that dual vaccination against IL-4 and IL-13 induces their durable suppression ameliorate experimental asthma, and to hint clinical translation.
